Q4 2024 EPS Estimates for Quest Diagnostics Incorporated Boosted by Analyst (NYSE:DGX)

Quest Diagnostics Incorporated (NYSE:DGX) – Equities research analysts at William Blair increased their Q4 2024 EPS estimates for Quest Diagnostics in a research note issued to investors on Tuesday, July 23rd. William Blair analyst A. Brackmann now forecasts that the medical research company will post earnings per share of $2.20 for the quarter, up from their previous forecast of $2.18. The consensus estimate for Quest Diagnostics’ current full-year earnings is $8.89 per share. William Blair also issued estimates for Quest Diagnostics’ Q3 2025 earnings at $2.45 EPS and Q4 2025 earnings at $2.40 EPS.

Quest Diagnostics (NYSE:DGX) last issued its earnings results on Tuesday, July 23rd. The medical research company reported $2.35 EPS for the quarter, beating the consensus estimate of $2.31 by $0.04. The company had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.39 billion. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.35%. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period in the previous year, the company earned $2.30 EPS.

DGX has been the topic of several other reports. UBS Group boosted their price target on Quest Diagnostics from $139.00 to $146.00 and gave the company a “neutral” rating in a research note on Wednesday, April 24th. Truist Financial boosted their price target on shares of Quest Diagnostics from $150.00 to $158.00 and gave the stock a “hold” rating in a report on Monday, July 15th. Barclays lifted their target price on shares of Quest Diagnostics from $138.00 to $144.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 25th. Mizuho raised their price target on shares of Quest Diagnostics from $150.00 to $155.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Finally, JPMorgan Chase & Co. lifted their price target on Quest Diagnostics from $152.00 to $155.00 and gave the stock a “neutral” rating in a research note on Thursday, May 30th. Nine equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Quest Diagnostics has an average rating of “Hold” and a consensus price target of $149.38.

Quest Diagnostics Trading Up 0.2 %

DGX opened at $144.25 on Friday. The company’s 50 day moving average price is $141.10 and its two-hundred day moving average price is $134.46. Quest Diagnostics has a fifty-two week low of $119.59 and a fifty-two week high of $150.59. The firm has a market capitalization of $16.02 billion, a price-to-earnings ratio of 19.41, a PEG ratio of 3.05 and a beta of 0.89. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.00 and a quick ratio of 0.89.

Institutional Trading of Quest Diagnostics

Several large investors have recently modified their holdings of the company. Altshuler Shaham Ltd purchased a new position in Quest Diagnostics during the fourth quarter valued at $26,000. Spartan Planning & Wealth Management bought a new position in shares of Quest Diagnostics during the 4th quarter valued at approximately $31,000. Alaska Permanent Fund Corp raised its position in Quest Diagnostics by 79.3% in the 4th quarter. Alaska Permanent Fund Corp now owns 242 shares of the medical research company’s stock worth $33,000 after purchasing an additional 107 shares during the period. Riverview Trust Co purchased a new position in Quest Diagnostics during the 1st quarter valued at $33,000. Finally, TruNorth Capital Management LLC bought a new position in shares of Quest Diagnostics in the second quarter worth about $33,000. Institutional investors own 88.06% of the company’s stock.

Insiders Place Their Bets

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 1,760 shares of the firm’s stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $140.00, for a total transaction of $246,400.00. Following the completion of the sale, the senior vice president now directly owns 13,435 shares in the company, valued at approximately $1,880,900. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.79% of the company’s stock.

Quest Diagnostics Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, July 22nd. Shareholders of record on Monday, July 8th were issued a $0.75 dividend. The ex-dividend date of this dividend was Monday, July 8th. This represents a $3.00 dividend on an annualized basis and a yield of 2.08%. Quest Diagnostics’s dividend payout ratio (DPR) is 40.38%.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.